subject area of
- A Combination of Chemotherapy and Oncolytic Virotherapy Sensitizes Colorectal Adenocarcinoma to Immune Checkpoint Inhibitors in a cDC1-Dependent Manner Academic Article
- A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial Academic Article
- A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. Academic Article
- A let-7 MicroRNA-sensitive Vesicular Stomatitis Virus Demonstrates Tumor-specific Replication Academic Article
- A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213. Academic Article
- A rational relationship: Oncolytic virus vaccines as functional partners for adoptive T cell therapy Academic Article
- Adaptive Antiviral Immunity Is a Determinant of the Therapeutic Success of Oncolytic Virotherapy Academic Article
- Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination Academic Article
- An Optimized Clinical Regimen for the Oncolytic Virus PV701 Academic Article
- Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines Academic Article
- Bovine herpesvirus type 1 as a novel oncolytic virus Academic Article
- CD8+ T-cell expansion and maintenance after recombinant adenovirus immunization rely upon cooperation between hematopoietic and nonhematopoietic antigen-presenting cells Academic Article
- Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy Academic Article
- Characterization of the Impact of Oncolytic Vesicular Stomatitis Virus on the Trafficking, Phenotype, and Antigen Presentation Potential of Neutrophils and Their Ability to Acquire a Non-Structural Viral Protein Academic Article
- Combining Oncolytic HSV-1 with Immunogenic Cell Death-Inducing Drug Mitoxantrone Breaks Cancer Immune Tolerance and Improves Therapeutic Efficacy Academic Article
- Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer Academic Article
- Combining oncolytic virotherapy and tumour vaccination Academic Article
- Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies Academic Article
- Customized Viral Immunotherapy for HPV-Associated Cancer Academic Article
- Cytokines in oncolytic virotherapy Academic Article
- De novo necroptosis creates an inflammatory environment mediating tumor susceptibility to immune checkpoint inhibitors Academic Article
- Deciphering the Immunomodulatory Capacity of Oncolytic Vaccinia Virus to Enhance the Immune Response to Breast Cancer Academic Article
- Detection of Tumor Antigen-Specific T-Cell Responses After Oncolytic Vaccination Academic Article
- Diplomatic immunity: turning a foe into an ally. Academic Article
- Effects of Intravenously Administered Recombinant Vesicular Stomatitis Virus (VSV ΔM51 ) on Multifocal and Invasive Gliomas Academic Article
- Evolution of oncolytic viruses: novel strategies for cancer treatment Academic Article
- Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity Academic Article
- Genetic modification of oncolytic viruses to enhance antitumor immunity Academic Article
- Genome-wide lentiviral shRNA screen identifies serine/arginine-rich splicing factor 2 as a determinant of oncolytic virus activity in breast cancer cells Academic Article
- Going viral with cancer immunotherapy Academic Article
- Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses Academic Article
- Harnessing Oncolytic Virus-mediated Antitumor Immunity in an Infected Cell Vaccine Academic Article
- Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells Academic Article
- Immunogenic HSV-mediated Oncolysis Shapes the Antitumor Immune Response and Contributes to Therapeutic Efficacy Academic Article
- Intelligent Design: Combination Therapy With Oncolytic Viruses Academic Article
- Maraba MG1 Virus Enhances Natural Killer Cell Function via Conventional Dendritic Cells to Reduce Postoperative Metastatic Disease Academic Article
- Multi-Stability and Multi-Instability Phenomena in a Mathematical Model of Tumor-Immune-Virus Interactions Academic Article
- Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression Academic Article
- Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy Academic Article
- ORFV: A Novel Oncolytic and Immune Stimulating Parapoxvirus Therapeutic Academic Article
- Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer Academic Article
- Oncolytic Virotherapy and Immunogenic Cancer Cell Death: Sharpening the Sword for Improved Cancer Treatment Strategies Academic Article
- Oncolytic Viruses: Therapeutics With an Identity Crisis Academic Article
- Oncolytic bovine herpesvirus type 1 as a broad spectrum cancer therapeutic Academic Article
- Oncolytic bovine herpesvirus type 1 infects and kills breast tumor cells and breast cancer-initiating cells irrespective of tumor subtype Academic Article
- PML has a predictive role in tumor cell permissiveness to interferon-sensitive oncolytic viruses Academic Article
- Panorama From the Oncolytic Virotherapy Summit Academic Article
- Permissiveness of Human Cancer Cells to Oncolytic Bovine Herpesvirus 1 Is Mediated in Part by KRAS Activity Academic Article
- Pre-surgical neoadjuvant oncolytic virotherapy confers protection against rechallenge in a murine model of breast cancer Academic Article
- Preclinical development of peptide vaccination combined with oncolytic MG1-E6E7 for HPV-associated cancer Academic Article
- Programmable insect cell carriers for systemic delivery of integrated cancer biotherapy Academic Article
- Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer Academic Article
- Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity Academic Article
- Strategies to Enhance Viral Penetration of Solid Tumors Academic Article
- Synergistic Interaction Between Oncolytic Viruses Augments Tumor Killing Academic Article
- Targeting Tumor Vasculature With an Oncolytic Virus Academic Article
- The role of oncolytic virus immunotherapies to subvert cancer immune evasion Academic Article
- Tumour vasculature: Friend or foe of oncolytic viruses? Academic Article
- Type I IFN blockade uncouples immunotherapy-induced antitumor immunity and autoimmune toxicity Academic Article
- Vesicular Stomatitis Virus Oncolytic Treatment Interferes with Tumor-Associated Dendritic Cell Functions and Abrogates Tumor Antigen Presentation Academic Article
- Vesicular stomatitis virus: re-inventing the bullet Academic Article